- Home
- DSGN vs LANV Comparison
DSGN vs LANV Comparison
Compare DSGN & LANV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- LANV
- Stock Information
- Founded
- DSGN 2017
- LANV 2015
- Country
- DSGN United States
- LANV China
- Employees
- DSGN N/A
- LANV N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- LANV Blank Checks
- Sector
- DSGN Health Care
- LANV Finance
- Exchange
- DSGN Nasdaq
- LANV Nasdaq
- Market Cap
- DSGN 208.9M
- LANV 258.1M
- IPO Year
- DSGN 2021
- LANV N/A
- Fundamental
- Price
- DSGN $3.67
- LANV $2.14
- Analyst Decision
- DSGN Hold
- LANV
- Analyst Count
- DSGN 1
- LANV 0
- Target Price
- DSGN $4.00
- LANV N/A
- AVG Volume (30 Days)
- DSGN 89.5K
- LANV 38.1K
- Earning Date
- DSGN 08-04-2025
- LANV 08-25-2025
- Dividend Yield
- DSGN N/A
- LANV N/A
- EPS Growth
- DSGN N/A
- LANV N/A
- EPS
- DSGN N/A
- LANV N/A
- Revenue
- DSGN N/A
- LANV $340,211,202.00
- Revenue This Year
- DSGN N/A
- LANV $11.74
- Revenue Next Year
- DSGN N/A
- LANV $11.11
- P/E Ratio
- DSGN N/A
- LANV N/A
- Revenue Growth
- DSGN N/A
- LANV N/A
- 52 Week Low
- DSGN $2.60
- LANV $0.91
- 52 Week High
- DSGN $7.77
- LANV $2.69
- Technical
- Relative Strength Index (RSI)
- DSGN 48.40
- LANV 46.96
- Support Level
- DSGN $3.65
- LANV $2.00
- Resistance Level
- DSGN $4.21
- LANV $2.21
- Average True Range (ATR)
- DSGN 0.23
- LANV 0.12
- MACD
- DSGN -0.00
- LANV 0.00
- Stochastic Oscillator
- DSGN 23.81
- LANV 57.89
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About LANV Lanvin Group Holdings Limited
Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the Wolford segment.